Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
Go back to Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 34.61 -0.06 (0.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.67 | 52 Week High | $117.12 | |||
| Open | $34.71 | 52 Week Low | $46.52 | |||
| Day High | $34.81 | P/E | N/A | |||
| Day Low | $33.34 | EPS | $-1.97 | |||
| Volume | 1,942,585 | |||||
